PD-L1 Solid Tumors clinical trials
27 active Solid Tumors trials that test for PD-L1 in their eligibility criteria. Describe your situation to see which ones look like a fit.
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
- VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
- Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
- A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
- Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
- A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
- A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- FOG-001 in Locally Advanced or Metastatic Solid Tumors
- A Study of ASP1002 in Adults for Treatment of Solid Tumors
- A Study of CRD3874-SI in People With Solid Tumors
- A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
- DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
- A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- A Study of TAK-505 in Adults With Solid Tumors
- A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
- Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
- A Study of a Side Effects and Resource Navigation Program for People With Cancer
- A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
- A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
- Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.